Phenotypic Screening for Diabetes Drugs

Human Cell Modelling of Rare Diseases

Custom Liver Disease Model Development

Disease Models to Reposition Your Drugs

DefiniGEN Products & Services


DefiniGEN are a Cambridge UK company providing highly functional human cell products including liver, pancreas, lung, and intestinal cells plus custom services for drug discovery and disease model generation. Our proprietary platform technology OptiDIFF delivers our products and custom services including induced Pluripotent Stem Cell (iPSC) generation, CRISPR-CAS9 gene editing, iPSC differentiation and custom disease model development.

Our ground-breaking OptiDIFF differentiation system utilizes GMP-compatible conditions to generate human cell products which have similar function and performance to primary human cells on an industrial scale. The provision of high quality QC tested cell products with the functionality of primary cells enables you to accelerate your research and optimise your workflow.


Platform Technology Key Publications

Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation. Sampaziotis F, Cardoso de Brito M, Madrigal P, Bertero A, Saeb-Parsy K, Soares FA, Schrumpf E, Melum E, Karlsen TH, Bradley JA, Gelson WT, Davies S, Baker A, Kaser A, Alexander GJ, Hannan NR, Vallier L. Nat Biotechnol. 2015 Aug;33(8):845-52.

Generation of Distal Airway Epithelium from Multipotent Human Foregut Stem Cells. Hannan NR, Sampaziotis F, Segeritz CP, Hanley NA, Vallier L. Stem Cells Dev. 2015 Jul 15;24(14):1680-90.

Generation of multipotent foregut stem cells from human pluripotent stem cells. Hannan NR, Fordham RP, Vallier L, et al. Stem Cell Reports. 2013 Oct 10;1(4):293-306

Inhibition of activin/nodal signalling is necessary for pancreatic differentiation of human pluripotent stem cells. Cho CH, Hannan NR, Docherty FM, Docherty HM, Joåo Lima M, Trotter MW, Docherty K, Vallier L. Diabetologia. 2012 Sep 26.

Pancreatic transcription factors containing protein transduction domains drive mouse embryonic stem cells towards endocrine pancreas. Lima MJ, Docherty HM, Chen Y, Vallier L, Docherty K. PLoS One. 2012;7(5):e36481. Epub 2012 May 1.

Status of genomic imprinting in epigenetically distinct pluripotent stem cells. Sun B, Ito M, Mendjan S, Ito Y, Brons IG, Murrell A, Vallier L, Ferguson-Smith AC, Pedersen RA. Stem Cells. 2012 Feb;30(2):161-8.

The serpinopathies studying serpin polymerization in vivo. Irving JA, Ekeowa UI, Belorgey D, Haq I, Gooptu B, Miranda E, Pérez J, Roussel BD, Ordóñez A, Dalton LE, Thomas SE, Marciniak SJ, Parfrey H, Chilvers ER, Teckman JH, Alam S, Mahadeva R, Rashid ST, Vallier L, Lomas DA. Methods Enzymol. 2011;501:421-66.

Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Yusa K, Rashid ST, Strick-Marchand H, Varela I, Liu PQ, Paschon DE, Miranda E, Ordóñez A, Hannan NR, Rouhani FJ, Darche S, Alexander G, Marciniak SJ, Fusaki N, Hasegawa M, Holmes MC, Di Santo JP, Lomas DA, Bradley A, Vallier L. Nature. 2011 Oct 12;478(7369):391-4.

Serum-free and feeder-free culture conditions for human embryonic stem cells. Vallier L. Methods Mol Biol. 2011;690:57-66.

Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. Rashid ST, Corbineau S, Hannan N, Marciniak SJ, Miranda E, Alexander G, Huang-Doran I, Griffin J, Ahrlund-Richter L, Skepper J, Semple R, Weber A, Lomas DA, Vallier L. J Clin Invest. 2010 Sep;120(9):3127-36.

Robust differentiation of fetal hepatocytes from human embryonic stem cells and iPS. Touboul T, Vallier L, Weber A. Med Sci (Paris). 2010 Dec;26(12):1061-6. Review.